MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Comparison of the utility of three cognitive scales for MDS Level-I diagnosis of mild cognitive impairment in Parkinson’s disease: MoCA, PD-CRS and ACE-III

R. Fernandez-Bobadilla, J. Pagonabarraga, J.A. Matias-Guiu, S. Martínez-Horta, A. Horta-Barba, J. Marin-Lahoz, J. Perez-Perez, B. Pascual-Sedano, H. Bejr-Kasem, A. Campolongo, J. Kulisevsky (Barcelona, Spain)

Meeting: 2016 International Congress

Abstract Number: 1360

Keywords: Cognitive dysfunction, Dementia, Memory disorders

Session Information

Date: Wednesday, June 22, 2016

Session Title: Cognitive disorders

Session Time: 12:00pm-1:30pm

Location: Exhibit Hall located in Hall B, Level 2

Objective: To compare the utility for detecting Mild Cognitive Impairment in Parkinson’s disease (PD-MCI) of three abbreviated global scales: the Montreal Cognitive Assessment (MoCA), the Parkinson’s disease-Cognitive Rating Scale (PD-CRS) and the Addenbrooke’s Cognitive Examination new version (ACE-III).

Background: The Movement Disorders Society (MDS) proposed guidelines for diagnosing PD-MCI including two assessment levels: abbreviated (Level-I) and comprehensive (Level-II). The availability of cognitive scales adapted to new MDS criteria with high discriminative abilities can improve the precision of PD-MCI identification in a clinical setting.

Methods: The study sample included early PD patients (≤5 years from diagnosis) with normal cognition (PD-NC) or PD-MCI based on Level-II MDS criteria (two tests within each cognitive domain). Receiver operator curve (ROC) analyses were generated to calculate the area under the curve (AUC) and to measure the sensitivity and specificity of the cutoff scores from the Level-I scales. To examine the utility as screening tools, the optimal cutoff was defined as the lowest value providing ≥80% sensitivity (SEN). To use them as diagnostic tools, the optimal cutoff was the highest value providing ≥80% specificity (SPE).

Results: After screening for inclusion criteria, 71 PD patients [53.5% males; age= 68.7 (10.0SD) years; education=11.5 (4.9SD) years; PD evolution= 2.0 (1.7SD) years] completed the assessment.

Demographical and clinical data
  Total (n=71) PD-NC (n=51) PD-MCI (n=20) P value t-test (PD-NC vs PD-MCI)
  mean (SD) mean (SD) mean (SD)  
Age (years) 68.7 (10.0) 66.9 (10.6) 73.0 (6.7) 0.006
Gender, n Males (%) 38 (53.5) 29 (56.9) 9 (45.0) N.S
Education (years) 11.5 (4.9) 12.2 (4.4) 9.7 (5.8) N.S
PD Evolution (years) 2.0 (1.7) 1.9 (1.7) 2.0 (1.8) N.S
HADS Depression 3.2 (3.1) 3.1 (2.8) 3.7 (3.8) N.S
HADS Anxiety 5.2 (4.1) 5.5 (4.2) 9.4 (7.4) N.S
PD-CFRS 1.7 (1.9) 1.3 (1.8) 2.8 (2.0) 0.004
HADS = Hospital Anxiety and Depression Scale; PD-CFRS = Parkinson’s disease – Cognitive Functional Rating Scale” Twenty patients were diagnosed as PD-MCI (28.2%) and 51 as PD-NC.

Cognitive Assessment results
Task (max) PD-NC (n=51) PD-MCI (n=20) P value
MDS Level-I mean (SD) mean (SD)  
MoCA (30) 25.9 (2.8) 21.9 (3.2) <0.001
PD-CRS (134) 94.8 (12.2) 72.2 (9.0) <0.001
ACE-III (100) 91.7 (6.8) 80.0 (8.3) <0.001
MDS Level-II      
Attention & WM      
TMT-A (sg) 52.2 (17.3) 90.6 (32.3) <0.001
Digits Backward (max span) 3.9 (0.9) 2.9 (0.8) <0.001
Executive Function      
TMT-B (sg) 137.3 (69.1) 341.1 (144.1) <0.001
Phonetic Fluency 16.2 (4.3) 10.9 (3.9) <0.001
Memory      
FCSRT DFR 9.6 (3.4) 5.2 (3.1) <0.001
ROCF 30′ 12.7 (6.7) 5.1 (4.3) <0.001
Language      
BNT 54.5 (4.1) 49.7 (4.7) <0.001
Semantic Fluency 19.9 (5.7) 13.8 (4.5) <0.001
Visuospatial Function      
JLOT 21.6 (4.8) 16.4 (5.3) <0.001
VOSP Number Location 8.1 (1.3) 7.2 (2.5) 0.07 N.S.
TMT= Trail Making Test; FCSRT DFR= Free and Cued Selective Remining Test delayed free recall; ROCF= Rey-Osterrieth Complex Figure; BNT= Boston Naming Test; JLOT= Judgment of Line Orientation Test; VOSP= Visual Object and Space Perception battery PD-MCI group was significantly older and presented a worst performance in every cognitive measure. ROC analyses for the ACE-III (AUC=0.874) showed that the optimal cutoff score for PD-MCI screening was <89/100 (SEN=0.80; SPE=0.76) and for diagnostic purposes was <88/100 (SEN=0.75; SPE=0.84). For the MoCA (AUC=0.820) the optimal cutoff score for screening was <25/30 (SEN=0.80; SPE=0.74) and for diagnostic purposes was <24/30 (SEN=0.70; SPE=0.80). For the PD-CRS (AUC=0.930) a total score of <83/134 for global purposes yielded the best balance (SEN=0.80; SPE=0.82).

Conclusions: The PD-CRS shows the best performance as a diagnostic tool for PD-MCI, compared to the MoCA and the ACE-III results. These findings support the MDS recommendation allowing the application of an abbreviated assessment option to identify PD-MCI in non-demented PD patients.

To cite this abstract in AMA style:

R. Fernandez-Bobadilla, J. Pagonabarraga, J.A. Matias-Guiu, S. Martínez-Horta, A. Horta-Barba, J. Marin-Lahoz, J. Perez-Perez, B. Pascual-Sedano, H. Bejr-Kasem, A. Campolongo, J. Kulisevsky. Comparison of the utility of three cognitive scales for MDS Level-I diagnosis of mild cognitive impairment in Parkinson’s disease: MoCA, PD-CRS and ACE-III [abstract]. Mov Disord. 2016; 31 (suppl 2). https://www.mdsabstracts.org/abstract/comparison-of-the-utility-of-three-cognitive-scales-for-mds-level-i-diagnosis-of-mild-cognitive-impairment-in-parkinsons-disease-moca-pd-crs-and-ace-iii/. Accessed May 24, 2025.
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2016 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/comparison-of-the-utility-of-three-cognitive-scales-for-mds-level-i-diagnosis-of-mild-cognitive-impairment-in-parkinsons-disease-moca-pd-crs-and-ace-iii/

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • An Apparent Cluster of Parkinson's Disease (PD) in a Golf Community
  • The hardest symptoms that bother patients with Parkinson's disease
  • Life expectancy with and without Parkinson’s disease in the general population
  • Patients with Essential Tremor Live Longer than their Relatives
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • An Apparent Cluster of Parkinson's Disease (PD) in a Golf Community
  • The hardest symptoms that bother patients with Parkinson's disease
  • Life expectancy with and without Parkinson’s disease in the general population
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley